A study of the German Glioma Network studied a prospectively collected cohort of 233 glioblastoma patients aged 70 or older and found that patients with MGMT methylated tumors had longer progression-free survival when treated with radio- and chemotherapy or chemotherapy only as compared to patients treated with radiotherapy alone. This evidence concerns the gene MGMT and glioma.